NCT05474560View on ClinicalTrials.gov

Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 28, 2023

Study Completion Date

January 28, 2023

Conditions
Non-Alcoholic Fatty Liver DiseaseHyperuricemia
Interventions
DRUG

Allopurinol (100 mg/day) plus lifestyle intervention

participants accept allopurinol treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).

DRUG

Febuxostat 40 mg plus lifestyle intervention

participants accept Febuxostat treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).

BEHAVIORAL

Life style intervention

According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).

Trial Locations (1)

Unknown

National Hepatology and tropical medicine research institute, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT05474560 - Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients | Biotech Hunter | Biotech Hunter